An Early Surprise Win For BMS’s Opdivo/Yervoy In Lung Cancer

 
• By Mary Jo Laffler

CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.

Digital illustration of lung cancer cells in color background

More from Clinical Trials

More from R&D